Risk-adapted use of intravesical immunotherapy
Author:
Publisher
Wiley
Subject
Urology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1464-410X.2008.07968.x/fullpdf
Reference88 articles.
1. Jones JS Campbell SC Non-muscle-invasive bladder cancer (Ta, T1, CIS) Wein AJ Kavoussi LR Novick AC Partin AW Peters CA Campbell-Walsh Urology 9th edn WB Saunders 2007 2447 67
2. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials;Sylvester;J Urol,2002
3. Multivariate analysis of the prognostic factors of primary superficial bladder cancer;Millan-Rodriguez;J Urol,2000
4. Intravesical bacillus Calmette-Guèrin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials;Shelley;BJU Int,2004
5. Intravesical bacille Calmette-Guèrin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression;Böhle;Urology,2004
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Bacillus Calmette-Guérin pneumonitis after intravesical instillation: Report of two cases and a review of the literature;Biomedical Papers;2023-01-02
2. Impact of Effective Intravesical Therapies on Quality of Life in Patients with Non-Muscle Invasive Bladder Cancer: A Systematic Review;International Journal of Environmental Research and Public Health;2022-08-30
3. A prospective comparative study to assess the efficacy and tolerability of 2 different doses of intravesical bacillus Calmette-Guerin (BCG) in patients with non–muscle-invasive bladder cancer;Urologic Oncology: Seminars and Original Investigations;2020-05
4. Utilization of novel self-nanoemulsifying formulations (SNEFs) loaded paclitaxel for the treatment prosperity of bladder cancer;Journal of Drug Delivery Science and Technology;2020-04
5. Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer;Cochrane Database of Systematic Reviews;2020-01-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3